Compare GLP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | ANAB |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | 2017 |
| Metric | GLP | ANAB |
|---|---|---|
| Price | $48.46 | $52.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $45.00 | ★ $60.18 |
| AVG Volume (30 Days) | 46.4K | ★ 441.9K |
| Earning Date | 02-27-2026 | 03-02-2026 |
| Dividend Yield | ★ 6.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $18,099,776,000.00 | $169,467,000.00 |
| Revenue This Year | $22.70 | $135.51 |
| Revenue Next Year | $42.12 | N/A |
| P/E Ratio | $23.43 | ★ N/A |
| Revenue Growth | 4.10 | ★ 196.42 |
| 52 Week Low | $39.58 | $13.99 |
| 52 Week High | $60.00 | $57.65 |
| Indicator | GLP | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 59.78 |
| Support Level | $45.85 | $46.85 |
| Resistance Level | $47.75 | $56.39 |
| Average True Range (ATR) | 1.24 | 3.61 |
| MACD | 0.12 | 0.48 |
| Stochastic Oscillator | 90.62 | 64.57 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).